AGP Executive Report
Last update: 8 hours agoSwiss Pharma & Jobs: Novartis plans to discontinue small-volume biologics production at its Kleinbasel site by end-2027, potentially cutting around 130 jobs, while shifting cell-bank, testing and technical development work to Basel campus by end-2028. Banking Regulation: Swiss lawmakers move to soften UBS capital rules after an interim win in the fight over foreign unit capital demands, keeping the debate on how much regulation is “enough” for global banks. Markets & Rates: European stocks slipped as oil rose on Middle East tensions and bond-yield fears returned; Switzerland’s SMI managed a small gain on late buying. Tokenised Finance: Zug-based Centrifuge says tokenised assets hit about $1.6bn in value locked, with holders up 23% in a month, led by Janus Henderson-managed tokenised US Treasuries and CLO exposure. Swiss Business Abroad: ADAPT Investment Managers opened its fourth global office in Abu Dhabi to deepen MENA coverage, joining existing Geneva, Zug and New York operations. Trade & Food: Egyptian Swiss Group prepares to export pasta and flour to China for the first time after completing customs and regulatory steps. Health Innovation: EU approves Hopledo (modified-release carbidopa/levodopa) for Parkinson motor fluctuations, with phased rollout expected from October 2026.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
